Lofexidine

The dosing of lofexidine is highly specific and must be tailored to the severity of the withdrawal symptoms and the patient's tolerance.

• Standard Starting Dose: The usual recommended dosage is 0.54 mg (three 0.18 mg tablets) taken orally four times daily during the period of peak withdrawal symptoms.
• Dosing Frequency: Doses should be administered at intervals of 5 to 6 hours.
• Maximum Dose: The total daily dose should not exceed 2.88 mg (16 tablets per day), and no single dose should exceed 0.72 mg (4 tablets).
• Duration of Treatment: Treatment typically lasts for 7 to 14 days, depending on the half-life of the opioid being discontinued (e.g., shorter for heroin, longer for methadone).
• Tapering: When discontinuing lofexidine, the dose should be gradually reduced (tapered) over 2 to 4 days to prevent rebound hypertension (a sudden spike in blood pressure).

• Safety and Efficacy: The safety and effectiveness of lofexidine in pediatric patients (under the age of 18) have not been established.
• Recommendation: Lofexidine is currently NOT approved for pediatric use. Clinical trials have focused exclusively on the adult population.

Renal Impairment

Lofexidine is primarily cleared by the kidneys. In patients with kidney disease, the drug can accumulate, increasing the risk of side effects like bradycardia (slow heart rate) and hypotension (low blood pressure).

• Mild Impairment (CLcr 60-89 mL/min): No adjustment typically needed.
• Moderate Impairment (CLcr 30-59 mL/min): The dose should be reduced. A common adjustment is 0.36 mg three to four times daily.
• Severe Impairment/ESRD (CLcr < 30 mL/min): Further reduction is required, often starting at 0.18 mg three to four times daily.

Hepatic Impairment

Since lofexidine is metabolized by the liver, patients with hepatic impairment require monitoring.

• Mild to Moderate (Child-Pugh A or B): Dosage reduction is recommended. Healthcare providers may start with 0.36 mg three times daily.
• Severe (Child-Pugh C): Use is generally not recommended, or requires extreme caution with minimal dosing (0.18 mg doses).

Elderly Patients

Clinical studies of lofexidine did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently. However, because elderly patients are more likely to have decreased renal function and are more sensitive to blood pressure changes, they should start at the lowest possible dose with frequent monitoring of vital signs.

• Administration: Tablets should be swallowed whole with a full glass of water. They can be taken with or without food.
• Consistency: It is vital to take the medication at the same times each day to maintain steady levels in the bloodstream.
• Monitoring: Patients should be encouraged to monitor their own blood pressure and heart rate if possible, especially during the first few days of treatment.
• Storage: Store at room temperature (20°C to 25°C / 68°F to 77°F) in a dry place, away from light and moisture. Keep the bottle tightly closed.

If you miss a dose of lofexidine, take it as soon as you remember. However, if it is almost time for your next scheduled dose (within 2 hours), skip the missed dose and return to your regular schedule. Do not double the dose to catch up, as this significantly increases the risk of a dangerous drop in blood pressure or heart rate.

An overdose of lofexidine can be life-threatening.

• Signs of Overdose: Severe hypotension (fainting, dizziness), extreme bradycardia (very slow pulse), excessive sedation, somnolence (unusual sleepiness), and potentially respiratory depression.
• Emergency Measures: If an overdose is suspected, call 911 or seek emergency medical attention immediately. Treatment involves supportive care, intravenous fluids to raise blood pressure, and potentially medications like atropine to increase the heart rate.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation can cause your blood pressure to rise rapidly.

Lofexidine affects the autonomic nervous system, which can lead to several predictable side effects. The most common include:

• Orthostatic Hypotension: A sudden drop in blood pressure that occurs when standing up from a sitting or lying position. This may feel like a 'head rush,' dizziness, or lightheadedness. It is most common during the first 2-4 days of treatment.
• Bradycardia: A slowing of the heart rate. Patients may feel a slow pulse or a sensation of the heart 'skipping' a beat.
• Somnolence (Drowsiness): A significant feeling of sleepiness or lethargy. This can impair the ability to perform tasks requiring alertness.
• Dry Mouth (Xerostomia): A decrease in saliva production, which can lead to discomfort or difficulty swallowing.
• Dizziness: A general sense of unsteadiness or vertigo.

• Syncope (Fainting): Brief loss of consciousness due to low blood pressure.
• Insomnia: Despite the potential for daytime drowsiness, some patients find it difficult to sleep at night during withdrawal.
• Tinnitus: Ringing or buzzing in the ears.
• Hyperhidrosis: Increased sweating (though this can be difficult to distinguish from withdrawal symptoms themselves).

• QT Prolongation: A change in the electrical activity of the heart that can lead to dangerous heart rhythms.
• Rebound Hypertension: A significant increase in blood pressure after stopping the medication too quickly.
• Allergic Reactions: Rash, itching, or hives.

> Warning: Stop taking Lofexidine and call your doctor immediately if you experience any of these serious symptoms:

• Severe Hypotension: Feeling like you are going to pass out every time you stand up, or actual fainting spells.
• Extreme Bradycardia: A heart rate that drops below 50 beats per minute, accompanied by shortness of breath or chest pain.
• Cardiac Arrhythmias: Palpitations, a racing heart, or a feeling of fluttering in the chest (signs of QT prolongation).
• Signs of a Stroke: Sudden numbness or weakness (especially on one side of the body), sudden severe headache, or slurred speech (this can occur if blood pressure spikes during discontinuation).
• Severe Allergic Reaction (Anaphylaxis): Swelling of the face, lips, or tongue; difficulty breathing; or a widespread skin rash.

Lofexidine is not intended for long-term use. Most clinical trials have limited exposure to 14 days. Consequently, the long-term side effects are not well-characterized. However, chronic use of alpha-2 agonists can lead to:

• Tolerance: The medication may become less effective over time.
• Dependency: While not addictive in the way opioids are, the body may become accustomed to the drug's effect on blood pressure, making withdrawal from lofexidine itself difficult if not tapered.
• Depression: Some patients may experience a worsening of mood with prolonged use of central sympatholytic agents.

No FDA black box warnings for Lofexidine.

However, the FDA does emphasize the risk of hypotension, bradycardia, and QT prolongation in the 'Warnings and Precautions' section of the official label. It is critical that patients are monitored for these cardiovascular effects throughout the duration of treatment.

Report any unusual symptoms to your healthcare provider. Monitoring your heart rate and blood pressure at home can be a helpful way to track how your body is responding to the medication.

Lofexidine is a potent medication that significantly impacts the cardiovascular system. It should only be used as part of a comprehensive treatment program for opioid withdrawal. Patients must be aware that while lofexidine treats the physical symptoms of withdrawal, it does not treat the underlying addiction. Furthermore, after completing withdrawal with lofexidine, a patient's tolerance to opioids is significantly reduced. Resuming opioid use at previous doses can lead to a fatal overdose.

No FDA black box warnings for Lofexidine.

• Hypotension and Bradycardia: Lofexidine can cause significant decreases in blood pressure and heart rate. Patients should be advised to move slowly from a sitting or lying position to standing. If you feel dizzy or faint, sit or lie down immediately.
• QT Prolongation: This medication can prolong the QT interval (the time it takes for the heart's electrical system to recharge). This risk is increased in patients with a history of 'Long QT Syndrome,' those with low potassium or magnesium levels, or those taking other medications that affect the heart rhythm.
• CNS Depression: Lofexidine causes sedation. Using it with other central nervous system (CNS) depressants like alcohol, benzodiazepines (e.g., Xanax, Valium), or sleep medications can lead to dangerous levels of respiratory depression and sedation.
• Rebound Hypertension: Stopping lofexidine abruptly can cause a 'rebound' effect where blood pressure spikes higher than it was before treatment. This can be dangerous and lead to hypertensive crisis. Always follow a tapering schedule provided by your doctor.

Before and during treatment with lofexidine, your healthcare provider will likely perform the following:

• Baseline ECG: To check your heart's electrical rhythm and QT interval.
• Vital Signs: Frequent monitoring of blood pressure and pulse, especially before each dose escalation.
• Electrolytes: Blood tests to ensure potassium and magnesium levels are normal, as imbalances increase the risk of heart rhythm problems.
• Renal and Hepatic Function: Blood tests (Creatinine, ALT/AST) to ensure the liver and kidneys can process the drug safely.

Lofexidine can cause significant drowsiness, dizziness, and blurred vision. You should not drive, operate heavy machinery, or engage in potentially dangerous activities until you know how the medication affects you. Most patients should avoid these activities during the first few days of treatment.

Alcohol should be strictly avoided while taking lofexidine. Alcohol increases the sedative effects of the drug and can further lower blood pressure, increasing the risk of fainting and accidents.

Do not stop taking lofexidine suddenly. Your doctor will provide a tapering schedule to gradually reduce the dose over 2 to 4 days. If you experience a sudden headache, confusion, or blurred vision during the tapering process, contact your doctor immediately as these may be signs of high blood pressure.

> Important: Discuss all your medical conditions with your healthcare provider before starting Lofexidine, especially if you have a history of heart disease, kidney disease, or stroke.

While there are few absolute contraindications, certain combinations are extremely high-risk:

• Strong CYP2D6 Inhibitors (e.g., Paroxetine): Medications that strongly block the enzyme responsible for breaking down lofexidine can cause drug levels to spike to toxic levels, leading to severe hypotension and bradycardia.
• Other Alpha-2 Agonists (e.g., Clonidine, Tizanidine): Using these together creates an additive effect that can dangerously suppress the central nervous system and cardiovascular function.

• Methadone: Both methadone and lofexidine can prolong the QT interval. When used together, the risk of a life-threatening heart rhythm (Torsades de Pointes) is significantly increased. Patients on methadone who are tapering and using lofexidine require frequent ECG monitoring.
• Beta-Blockers (e.g., Metoprolol, Atenolol): These also slow the heart rate. Combining them with lofexidine can cause severe bradycardia.
• CNS Depressants (Benzodiazepines, Barbiturates): Combining lofexidine with drugs like alprazolam or phenobarbital can lead to profound sedation and respiratory depression.

• Digoxin: Lofexidine may increase the effects of digoxin on the heart's conduction system, potentially leading to heart block.
• Antihypertensives: Taking lofexidine with other blood pressure medications (ACE inhibitors, diuretics) can cause blood pressure to drop too low.
• Oral Contraceptives: Some evidence suggests that hormonal contraceptives may slightly increase the plasma levels of lofexidine, though this is usually not clinically significant for short-term use.

• Alcohol: As mentioned, alcohol is a major interaction that increases sedation and hypotension.
• Grapefruit: While not as significant as with other drugs, grapefruit juice can weakly inhibit certain enzymes involved in metabolism; it is best avoided to ensure predictable drug levels.
• High-Fat Meals: Food does not change the total amount of drug absorbed, but a very high-fat meal might slightly delay the time it takes to reach peak levels. Consistency is key.

• St. John's Wort: This herbal supplement can induce enzymes that break down lofexidine, potentially making the medication less effective.
• Kava and Valerian Root: These supplements have sedative properties and can increase the drowsiness caused by lofexidine.
• Magnesium/Potassium Supplements: While not a negative interaction, ensure you are not taking excessive amounts unless directed, as electrolyte balance is critical for heart safety.

Lofexidine is not known to interfere significantly with common laboratory tests (such as glucose or cholesterol tests). However, it may affect specialized tests for catecholamines (like norepinephrine) in the urine or blood, as the drug naturally suppresses these levels. Always inform the lab if you are taking this medication.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is necessary to prevent dangerous cardiovascular complications.

Lofexidine must NEVER be used in the following circumstances:

• Severe Hypersensitivity: If you have had a documented allergic reaction to lofexidine hydrochloride or any of the inactive ingredients in the tablet (e.g., anaphylaxis, angioedema).
• Severe Bradycardia: Patients with a baseline heart rate significantly below 50-60 beats per minute should not start this medication as it will further slow the heart.
• Uncompensated Heart Failure: The drug's effect on heart rate and blood pressure can worsen the condition of a failing heart.

These conditions require a careful risk-benefit analysis by a physician:

• Recent Myocardial Infarction (Heart Attack): The cardiovascular stress of withdrawal combined with the drug's effects on heart rate can be risky.
• Advanced Renal Insufficiency: Because the drug is renally excreted, the risk of toxicity is high. If used, doses must be significantly reduced.
• Cerebrovascular Disease: Patients with a history of stroke or TIA (mini-stroke) may be more sensitive to the blood pressure fluctuations caused by lofexidine.
• Electrolyte Imbalance: Low potassium (hypokalemia) or low magnesium (hypomagnesemia) must be corrected before starting lofexidine due to the risk of QT prolongation.

While not strictly documented, patients who have had severe adverse reactions to other alpha-2 adrenergic agonists (such as clonidine or guanfacine) should be monitored closely, as they may experience similar side effects with lofexidine. However, an allergy to clonidine does not automatically mean an allergy to lofexidine, as their chemical structures differ.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of fainting or heart rhythm disorders, before prescribing Lofexidine.

• FDA Category: There are no adequate and well-controlled studies of lofexidine in pregnant women. In animal studies, lofexidine was associated with reduced fetal weight and increased skeletal variations at doses higher than the human equivalent.
• Risk-Benefit: Opioid withdrawal during pregnancy is associated with significant risks to the fetus, including fetal distress and premature birth. Generally, opioid agonist maintenance (methadone or buprenorphine) is the standard of care. Lofexidine should only be used if the potential benefit justifies the potential risk to the fetus.

• Passage into Milk: It is not known whether lofexidine or its metabolites are excreted in human milk. However, animal studies have shown the drug is present in the milk of lactating rats.
• Recommendations: Because of the potential for serious adverse reactions in the nursing infant (such as sedation and low blood pressure), breastfeeding is generally not recommended while taking lofexidine.

• Age Range: Lofexidine is not approved for use in patients under 18 years of age.
• Concerns: The developing cardiovascular system and brain may be more sensitive to the effects of alpha-2 agonists. Until more data is available, its use in children and adolescents is considered off-label and generally avoided.

• Risks: Patients over 65 are at a significantly higher risk for falls due to orthostatic hypotension. They are also more likely to have underlying heart or kidney disease.
• Pharmacokinetics: Renal clearance is often reduced in the elderly, leading to higher drug concentrations.
• Dosing: If used, the lowest effective dose should be employed, with constant monitoring of blood pressure.

• Dose Adjustment: Patients with moderate to severe renal impairment require significant dose reductions. For those with a GFR < 30 mL/min, the total daily dose is often capped at 0.72 mg (compared to the standard 2.88 mg).
• Dialysis: It is not known if lofexidine is removed by hemodialysis. Dosing should occur after dialysis sessions.

• Dose Adjustment: In patients with mild to moderate hepatic impairment (Child-Pugh A or B), the dose should be reduced. In severe impairment (Child-Pugh C), the drug should be avoided if possible, as the liver's ability to metabolize the drug is severely compromised.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have any history of organ dysfunction.

Lofexidine is a central alpha-2 adrenergic receptor agonist. Its primary site of action is the locus coeruleus, a nucleus in the pons (part of the brainstem) that is the principal site for synthesis of norepinephrine in the brain. During opioid withdrawal, the locus coeruleus becomes hyperactive. Lofexidine binds to the alpha-2A receptors on the surface of these neurons. This binding inhibits the enzyme adenylate cyclase, which leads to a decrease in intracellular cAMP. The end result is the inhibition of the neuron's firing and a significant reduction in the release of norepinephrine. By 'quieting' this area of the brain, lofexidine reduces the systemic 'adrenergic storm' that causes withdrawal symptoms.

• Dose-Response: There is a clear relationship between the dose of lofexidine and the reduction in withdrawal symptoms, as measured by the Short Opiate Withdrawal Scale (SOWS-Gossop). However, higher doses also correlate linearly with drops in blood pressure and heart rate.
• Onset: The onset of action is relatively rapid, with symptomatic relief often beginning within 1-2 hours of the first dose.
• Duration: The effect of a single dose lasts approximately 5-8 hours, which necessitates the four-times-daily dosing schedule.

| Parameter | Value |

|---|---|

| Bioavailability | ~90% |

| Protein Binding | ~55% |

| Half-life | 12 - 17 hours |

| Tmax | 3 - 5 hours |

| Metabolism | Hepatic (CYP2D6, CYP1A2, CYP3A4) |

| Excretion | Renal 92%, Fecal <1% |

• Molecular Formula: C11H12Cl2N2O
• Molecular Weight: 259.13 g/mol
• Solubility: Soluble in water and ethanol.
• Structure: Lofexidine is an imidazoline derivative, structurally related to clonidine but with an additional phenoxy group that increases its selectivity for the alpha-2A receptor subtype.

Lofexidine is classified as a central alpha-2 adrenergic agonist. It is therapeuticially categorized as a detoxification adjunct. Related medications include clonidine (used off-label for withdrawal) and guanfacine (used for ADHD and hypertension).